SOURCE: Neuronascent, Inc.

Neuronascent, Inc.

January 29, 2014 07:00 ET

Neuronascent, Inc. Announces Issuance of US Patent Covering Second-Generation Neurorestorative Therapeutic Candidate

CLARKSVILLE, MD--(Marketwired - Jan 29, 2014) - Neuronascent, Inc. announced today the issuance of the United States patent covering a new compound family that includes Neuronascent's lead candidate, NNI-370 for Parkinson's disease and other neurodegenerative disorders. This is an important expansion of the company's patent portfolio of small-molecule therapies for neurologic disorders.

"Neuronascent is focused on Parkinson's disease as another indication where our small-molecule therapy, that is both neuroprotective and neuroregenerative may be disease-modifying," said Judith Kelleher-Andersson, Ph.D., Founder, President and Chief Scientific Officer of Neuronascent. Neuronascent has added Charles Meshul, PhD., Professor, Department of Behavioral Neuroscience and Pathology at Oregon Health and Science University and Research Biologist for the Portland Oregon Veterans Administration, to its Scientific Advisory Board (SAB) to provide strategic guidance in further pursuit of this indication. Dr. Meshul has been working in the Parkinson's disease space for over 20 years on progressive models of disease and therapeutic targets. His research is currently funded by The Michael J. Fox Foundation and other agencies.

About NNI-370

NNI-370 is part of a larger molecular family that has been validated in neural cell assays that indicate not only neuroprotection against brain toxins, but induction of progenitor cells into new neurons, that are selectively lost in the region of the brain damaged in PD.

About Neuronascent

Neuronascent, Inc. is a pre-IND stage company developing orally available, novel neurogenic and neurorestorative therapeutics that target Parkinson's disease, Down syndrome, Alzheimer's disease and post-traumatic stress disorder.

Safe Harbor Statement

This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations.

Contact Information

  • Judith Kelleher-Andersson, Ph.D.
    President and CSO
    Email Contact